Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2012. The report serves as a notification of transactions involving a Person Discharging Managerial Responsibility (PDMR) in American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider trading activity rather than a financial performance report.
Material Changes
The material change disclosed is a reduction in the shareholding of Mr. W C Louv, a Person Discharging Managerial Responsibility. On September 28, 2012, he sold 9,964 ADSs at a price of $46.24 per ADS. The company was advised of this transaction on October 1, 2012.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly adheres to Disclosure Rule 3.1.4R(1)(a) regarding the notification of director and managerial transactions.
Investor Verification Points
- Verify the total remaining holdings of Mr. W C Louv following the sale of 9,964 ADSs.
- Confirm the market price of GSK ADSs on September 28, 2012, to contextualize the $46.24 transaction price.
- Review subsequent filings to determine if this transaction was part of a pre-arranged trading plan.